针对中国石油化工股份有限公司广州分公司的1.5 Mt/a S Zorb装置,考察了影响装置长周期平稳运行的因素。采取使用国产高通量滤芯及在转剂线上使用耐磨管件,对再生取热盘管进行改造,对闭锁料斗程控阀进行预防性维修等措施解决了装置长周...针对中国石油化工股份有限公司广州分公司的1.5 Mt/a S Zorb装置,考察了影响装置长周期平稳运行的因素。采取使用国产高通量滤芯及在转剂线上使用耐磨管件,对再生取热盘管进行改造,对闭锁料斗程控阀进行预防性维修等措施解决了装置长周期运行瓶颈,实现了在95.06%设计负荷工况下连续平稳运行超过49个月的目标,关键设备反应器过滤器运行超过4 a,期间压差未超过30 kPa。展开更多
CaO-based sorbent is considered to be a promising candidate for capturing CO_2 at high temperature. However,the adsorption capacity of CaO decreases sharply with the increase of the carbonation/calcination cycles. In ...CaO-based sorbent is considered to be a promising candidate for capturing CO_2 at high temperature. However,the adsorption capacity of CaO decreases sharply with the increase of the carbonation/calcination cycles. In this study, CaO was derived from calcium acetate(CaAc_2), which was doped with different elements(Mg, Al,Ce, Zr and La) to improve the cyclic stability. The carbonation conversion and cyclic stability of sorbents were tested by thermogravimetric analyzer(TGA). The sorbents were characterized by N_2 isothermal adsorption measurements, scanning electron microscopy(SEM) and X-ray diffraction(XRD). The results showed that the cyclic stabilities of all modified sorbents were improved by doping elements, while the carbonation conversions of sorbents in the 1st cycle were not increased by doping different elements. After 22 cycles, the cyclic stabilities of CaO–Al, CaO–Ce and CaO–La were above 96.2%. After 110 cycles, the cyclic stability of CaO–Al was still as high as 87.1%. Furthermore, the carbonation conversion was closely related to the critical time and specific surface area.展开更多
OBJECTIVE To evaluate the effect and safety of a Molecular Adsorbent Recycling System （MARS） in treating posthepatoectomy hepatic failure （AHF） patients surgically treated for primary hepatocellular carcinoma （HC...OBJECTIVE To evaluate the effect and safety of a Molecular Adsorbent Recycling System （MARS） in treating posthepatoectomy hepatic failure （AHF） patients surgically treated for primary hepatocellular carcinoma （HCC）. METHODS 12 AHF patients induced by resection of HCC were treated with MARS before orthotopic liver transplantation （OLT）. Their vital signs, urine volume, APACHElll and Glasgow scores were monitored. Routine laboratory blood tests, measurements of coagulatory function, liver and kidney function, serum ammonia, lactic acid and blood gas were conducted before and after treatment with MARS. All of the patients were followed up for a period of 6 months after OLT for prognosis and complication assessment. RESULTS Each patient was treated with MARS for 2-5 times （average of 3.6） with a length of 8-24 h each time. Their mean arterial blood pressure and urine volume were improved, APACHE III and Glasgow scores were better. Liver function was improved with the following alterations before and after treatment with MARS： serum ammonia （127.1±21.4 umol/L vs. 77.4±19.7 umol/L, P〈0.05）, lactic acid （6.53±0.45 mmol/L vs. 3.75± 0.40 mmol/L, P〈0.05） and total bilirubin （452.3±153.7 umol/L vs. 230.9± 115.2 umol/L, P〈0.05）. However, there was no significant change in platelet count （44.25±3.60×10^9/L vs. 43.19±8.26×10^9/L, P〉0.05） on international normalized ratio （INR） （2.74±0.50 vs. 2.82±0.60, P〉0.05）, which showed the safety of MARS. For all patients no serious adverse effects occurred during the treatment with MARS. CONCLUSION MARS is effective and safe for treatment of AHF patients with HCC, especially as a bridge to OLT when a donor organ is not available.展开更多
基金Supported by Capture CO_2 and Storage Technology Jointly Studied by USA and China(2013DFB60140-04)Northwest University Graduate Innovative Talent Training Project(YZZ12036)
文摘CaO-based sorbent is considered to be a promising candidate for capturing CO_2 at high temperature. However,the adsorption capacity of CaO decreases sharply with the increase of the carbonation/calcination cycles. In this study, CaO was derived from calcium acetate(CaAc_2), which was doped with different elements(Mg, Al,Ce, Zr and La) to improve the cyclic stability. The carbonation conversion and cyclic stability of sorbents were tested by thermogravimetric analyzer(TGA). The sorbents were characterized by N_2 isothermal adsorption measurements, scanning electron microscopy(SEM) and X-ray diffraction(XRD). The results showed that the cyclic stabilities of all modified sorbents were improved by doping elements, while the carbonation conversions of sorbents in the 1st cycle were not increased by doping different elements. After 22 cycles, the cyclic stabilities of CaO–Al, CaO–Ce and CaO–La were above 96.2%. After 110 cycles, the cyclic stability of CaO–Al was still as high as 87.1%. Furthermore, the carbonation conversion was closely related to the critical time and specific surface area.
文摘OBJECTIVE To evaluate the effect and safety of a Molecular Adsorbent Recycling System （MARS） in treating posthepatoectomy hepatic failure （AHF） patients surgically treated for primary hepatocellular carcinoma （HCC）. METHODS 12 AHF patients induced by resection of HCC were treated with MARS before orthotopic liver transplantation （OLT）. Their vital signs, urine volume, APACHElll and Glasgow scores were monitored. Routine laboratory blood tests, measurements of coagulatory function, liver and kidney function, serum ammonia, lactic acid and blood gas were conducted before and after treatment with MARS. All of the patients were followed up for a period of 6 months after OLT for prognosis and complication assessment. RESULTS Each patient was treated with MARS for 2-5 times （average of 3.6） with a length of 8-24 h each time. Their mean arterial blood pressure and urine volume were improved, APACHE III and Glasgow scores were better. Liver function was improved with the following alterations before and after treatment with MARS： serum ammonia （127.1±21.4 umol/L vs. 77.4±19.7 umol/L, P〈0.05）, lactic acid （6.53±0.45 mmol/L vs. 3.75± 0.40 mmol/L, P〈0.05） and total bilirubin （452.3±153.7 umol/L vs. 230.9± 115.2 umol/L, P〈0.05）. However, there was no significant change in platelet count （44.25±3.60×10^9/L vs. 43.19±8.26×10^9/L, P〉0.05） on international normalized ratio （INR） （2.74±0.50 vs. 2.82±0.60, P〉0.05）, which showed the safety of MARS. For all patients no serious adverse effects occurred during the treatment with MARS. CONCLUSION MARS is effective and safe for treatment of AHF patients with HCC, especially as a bridge to OLT when a donor organ is not available.
